<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299321</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-LAMA2-001</org_study_id>
    <nct_id>NCT04299321</nct_id>
  </id_info>
  <brief_title>Retrospective Natural History Study of LAMA2 in Infants and Toddlers</brief_title>
  <acronym>LAMA2 rTNHS</acronym>
  <official_title>LAMA2 Retrospective Review of Medical Charts in Infants &amp; Toddlers With LAMA2-CMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prothelia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cure CMD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Bönnemann Laboratory, NINDS, National Institutes of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oscar H Mayer, MD, Children’s Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Beggs Laboratory, Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Prothelia, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This retrospective chart review study of 75-120 LAMA2-CMD patients will expand the
      investigators understanding of the natural history of this disease. Current and pending
      publications cover research performed only in ages 5-16 years; there is currently no
      documented natural history for patients ages 0-5 years. Data collected in this study has the
      potential to inform the design of future interventional studies that draw nearer to clinical
      trial readiness every day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LAMA2-related congenital muscular dystrophy (LAMA2-CMD) is caused by a deficiency of the α2
      subunit of laminin due to mutation of the LAMA2 gene.

      Typical LAMA2-CMD cases present with prominent hypotonia and weakness in infancy. Congenital
      contractures are a common finding in the hands and feet. Weakness and contractures are slowly
      progressive, and most patients do not achieve independent ambulation. Facial weakness and jaw
      contractures disrupt normal feeding, resulting in failure to thrive. Most patients require
      nutrition support at an early age. Cardiac involvement is rare. In addition to neuromuscular
      aspects of the disorder, patients with LAMA2-CMD have central nervous system findings
      including prominent T2 and fluid-attenuated inversion recovery (FLAIR) abnormalities in the
      white matter on brain MRI. Despite the prominent changes on MRI, cognitive function is
      normal, although patients are at risk of seizures, which are seen in 30% of patients.

      A number of potential therapies are currently in development for LAMA2-CMD. A larger
      prospective natural history was conducted at the National Institutes of Health in LAMA2-CMD
      patients, ages 5-16 years of age, testing and validating a wide variety of outcome measures
      suitable for use in clinical trials. However, appropriate clinical outcome measures in
      younger patients (ages 0-5 years) have yet to be validated.

      Some treatments currently in development will almost certainly be more effective the earlier
      the treatment is administered. Given that there is a distinct lack of data for affected
      individuals less than 6 years of age, this study will be instrumental in building outcome
      measures appropriate in younger patients. In order to obtain regulatory authorization to
      launch clinical trials in affected individuals less than 6 years of age, a documented natural
      history for this age group must be demonstrated.

      The primary objective of this study is to characterize aspects of LAMA2-CMD in ages 0-5 years
      through medical chart review/data extraction, and participant survey. This study aims to
      derive clinical trial endpoints useful in conducting interventional trials in the near
      future.

      The secondary objectives of this study include identifying potential prognostic variables of
      LAMA2-CMD, identifying adverse events associated with LAMA2-CMD that warrant monitoring and
      potential preventative measures, and to grow the knowledge base of care standards and
      optimization to improve the patient's quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 23, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 23, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the natural history of LAMA2-CMD</measure>
    <time_frame>Birth to 5 years of age</time_frame>
    <description>To characterize aspects of LAMA2-CMD in ages 0-5 years through medical chart review/data extraction, and participant survey. This study aims to derive clinical trial endpoints useful in conducting interventional trials in the near future.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify potential prognostic variables of LAMA2-CMD</measure>
    <time_frame>Birth to 5 years of age</time_frame>
    <description>Overall analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To identify adverse events associated with LAMA2-CMD that warrant monitoring and potential preventative measures</measure>
    <time_frame>Birth to 5 years of age</time_frame>
    <description>Overall analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To grow the knowledge base of care standards and optimization to improve the patient's quality of life</measure>
    <time_frame>Birth to 5 years of age</time_frame>
    <description>Overall analysis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Merosin Deficient Congenital Muscular Dystrophy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Infants and toddlers affected by LAMA2-CMD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed with LAMA2-CMD through:

               1. genetic confirmation of two (2) pathogenic mutations in LAMA2 -OR-

               2. genetic confirmation of one (1) pathogenic mutation in LAMA2, and supporting
                  clinical phenotype based on two or more of the following: physical examination,
                  brain imaging, muscle imaging, muscle biopsy, and creatine kinase (CK) levels
                  (blood test)

          2. Patients may be living or deceased

          3. Patients may be male or female

          4. Patients with available medical records between 2000-2017, documenting diagnosis,
             observation, and treatment between ages 0-5 years and a minimum set of data covering
             12-24 months during this age period.

          5. Patients with medical charts available in English

          6. Patients (or Parents of minor patients) who are able to consent to participation in
             English or Spanish, either directly, or through their own trusted interpreter

          7. Patients between the ages of 8-17 years who are able to provide assent to
             participation in English or Spanish, either directly, or through their own trusted
             interpreter

        Exclusion Criteria:

          1. Patients not diagnosed with LAMA2-CMD

          2. Patients with no available medical records documenting diagnosis, observation, and
             treatment between ages 0-5 years

          3. Patients with medical charts not available in English

          4. Patients (or Parents of minor patients) not able to consent to participation in
             English or Spanish, either directly, or through their own trusted interpreter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten Bönnemann, MD</last_name>
    <role>Study Director</role>
    <affiliation>NINDS/NIH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reghan Foley, MD</last_name>
    <role>Study Director</role>
    <affiliation>NINDS/NIH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oscar H Mayer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Beggs, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Justin Park, BS</last_name>
    <role>Study Chair</role>
    <affiliation>Cure CMD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo Dziewczapolski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cure CMD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rachel Alvarez, BS</last_name>
    <role>Study Director</role>
    <affiliation>Cure CMD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Justin Park, BS</last_name>
    <phone>(562) 444-5656</phone>
    <phone_ext>104</phone_ext>
    <email>lama2study@curecmd.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Alvarez, BS</last_name>
    <phone>(562) 444-5656</phone>
    <phone_ext>103</phone_ext>
    <email>rachel.alvarez@curecmd.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cure CMD, Inc.</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Justin Park, BS</last_name>
      <phone>562-444-5656</phone>
      <phone_ext>104</phone_ext>
      <email>lama2study@curecmd.org</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Alvarez, BS</last_name>
      <phone>562-444-5656</phone>
      <phone_ext>103</phone_ext>
      <email>rachel.alvarez@curecmd.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Foley AR, Quijano-Roy S, Collins J, Straub V, McCallum M, Deconinck N, Mercuri E, Pane M, D'Amico A, Bertini E, North K, Ryan MM, Richard P, Allamand V, Hicks D, Lamandé S, Hu Y, Gualandi F, Auh S, Muntoni F, Bönnemann CG. Natural history of pulmonary function in collagen VI-related myopathies. Brain. 2013 Dec;136(Pt 12):3625-33. doi: 10.1093/brain/awt284. Epub 2013 Nov 22.</citation>
    <PMID>24271325</PMID>
  </reference>
  <reference>
    <citation>Nadeau A, Kinali M, Main M, Jimenez-Mallebrera C, Aloysius A, Clement E, North B, Manzur AY, Robb SA, Mercuri E, Muntoni F. Natural history of Ullrich congenital muscular dystrophy. Neurology. 2009 Jul 7;73(1):25-31. doi: 10.1212/WNL.0b013e3181aae851.</citation>
    <PMID>19564581</PMID>
  </reference>
  <reference>
    <citation>Ditaranto R, Boriani G, Biffi M, Lorenzini M, Graziosi M, Ziacchi M, Pasquale F, Vitale G, Berardini A, Rinaldi R, Lattanzi G, Potena L, Martin Suarez S, Bacchi Reggiani ML, Rapezzi C, Biagini E. Differences in cardiac phenotype and natural history of laminopathies with and without neuromuscular onset. Orphanet J Rare Dis. 2019 Nov 19;14(1):263. doi: 10.1186/s13023-019-1245-8.</citation>
    <PMID>31744510</PMID>
  </reference>
  <reference>
    <citation>Durbeej M. Laminin-α2 Chain-Deficient Congenital Muscular Dystrophy: Pathophysiology and Development of Treatment. Curr Top Membr. 2015;76:31-60. doi: 10.1016/bs.ctm.2015.05.002. Review.</citation>
    <PMID>26610911</PMID>
  </reference>
  <reference>
    <citation>Jain MS, Meilleur K, Kim E, Norato G, Waite M, Nelson L, McGuire M, Duong T, Keller K, Lott DJ, Glanzman A, Rose K, Main M, Fiorini C, Chrismer I, Linton M, Punjabi M, Elliott J, Tounkara F, Vasavada R, Logaraj R, Winkert J, Donkervoort S, Leach M, Dastgir J, Hynan L, Nichols C, Hartnett E, Averion GM, Collins JC, Kim ES, Kokkinis A, Schindler A, Zukosky K, Fee R, Hinton V, Mohassel P, Bharucha-Goebel D, Vuillerot C, McGraw P, Barton M, Fontana J, Rutkowski A, Foley AR, Bönnemann CG. Longitudinal changes in clinical outcome measures in COL6-related dystrophies and LAMA2-related dystrophies. Neurology. 2019 Nov 19;93(21):e1932-e1943. doi: 10.1212/WNL.0000000000008517. Epub 2019 Oct 25.</citation>
    <PMID>31653707</PMID>
  </reference>
  <reference>
    <citation>Bendixen RM, Butrum J, Jain MS, Parks R, Hodsdon B, Nichols C, Hsia M, Nelson L, Keller KC, McGuire M, Elliott JS, Linton MM, Arveson IC, Tounkara F, Vasavada R, Harnett E, Punjabi M, Donkervoort S, Dastgir J, Leach ME, Rutkowski A, Waite M, Collins J, Bönnemann CG, Meilleur KG. Upper extremity outcome measures for collagen VI-related myopathy and LAMA2-related muscular dystrophy. Neuromuscul Disord. 2017 Mar;27(3):278-285. doi: 10.1016/j.nmd.2016.11.017. Epub 2016 Dec 5.</citation>
    <PMID>28087121</PMID>
  </reference>
  <reference>
    <citation>Fauroux B, Amaddeo A, Quijano-Roy S, Barnerias C, Desguerre I, Khirani S. Respiratory insight to congenital muscular dystrophies and congenital myopathies and its relation to clinical trial. Neuromuscul Disord. 2018 Sep;28(9):731-740. doi: 10.1016/j.nmd.2018.06.013. Epub 2018 Jul 1. Review.</citation>
    <PMID>30097248</PMID>
  </reference>
  <reference>
    <citation>Wicklund MP. Rare disease clinical trials: Power in numbers. Neurol Genet. 2016 Aug 4;2(4):e92. doi: 10.1212/NXG.0000000000000092. eCollection 2016 Aug.</citation>
    <PMID>27540592</PMID>
  </reference>
  <results_reference>
    <citation>Butterfield RJ. Congenital Muscular Dystrophy and Congenital Myopathy. Continuum (Minneap Minn). 2019 Dec;25(6):1640-1661. doi: 10.1212/CON.0000000000000792. Review.</citation>
    <PMID>31794464</PMID>
  </results_reference>
  <results_reference>
    <citation>Meilleur KG, Jain MS, Hynan LS, Shieh CY, Kim E, Waite M, McGuire M, Fiorini C, Glanzman AM, Main M, Rose K, Duong T, Bendixen R, Linton MM, Arveson IC, Nichols C, Yang K, Fischbeck KH, Wagner KR, North K, Mankodi A, Grunseich C, Hartnett EJ, Smith M, Donkervoort S, Schindler A, Kokkinis A, Leach M, Foley AR, Collins J, Muntoni F, Rutkowski A, Bönnemann CG. Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies. Neuromuscul Disord. 2015 Jan;25(1):43-54. doi: 10.1016/j.nmd.2014.09.010. Epub 2014 Sep 28.</citation>
    <PMID>25307854</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LAMA2</keyword>
  <keyword>LAMA2-CMD</keyword>
  <keyword>CMD</keyword>
  <keyword>MDC1A</keyword>
  <keyword>LAMA2-MD</keyword>
  <keyword>Merosin Deficient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will shared in a peer-reviewed publication. De-identified data will be used to inform future studies.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Available indefinitely through publication in approximately 18 months (August 2021)</ipd_time_frame>
    <ipd_access_criteria>Journal will have free access through PubMed</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

